This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
DMD · Western blot design guide
DMD Western Blot Planning Guide
Plan a DMD Western blot around the catalog-observed 426.8 kDa band, image-backed PB9276 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
DMD Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 426.8 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 4-12% gradient | |
| Positive control | Heart muscle | |
| Negative control | Appendix |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 426.8 kDa |
| ⓘ | Localization | Cell membrane, sarcolemma / Cytoplasm, cytoskeleton |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Sample controls for DMD Western blot
🧪Use Heart muscle as the first positive-control candidate and Appendix as the HPA Not detected negative candidate.
Positive control: Heart muscle (Medium)
Negative control: Appendix (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for DMD
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart on each tissue page — click any row's HPA link to view the source.
Section 1
What Is the Expected DMD Western Blot Band Size?
Use the product-observed 426.8 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 426.8 kDa | Matches the authoritative product WB observation. |
| 426.8 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected DMD appearancePlan around 426.8 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 426.8 kDa; use this as the primary experimental expectation. |
| Calculated mass | 426.8 kDa from UniProt P11532; retain as context. |
| Gel selection | 4-12% gradient; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9276. |
| Situation | Likely cause | Next action |
|---|---|---|
| 426.8 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing DMD band
PB9276 · DMDObserved 426.8 kDa · product-specific WB image
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Section 2
Real Curated DMD Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Heart muscle |
| Gel % | 4-12% gradient |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9276 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 4
Advanced DMD Western Blot Tips
Deeper troubleshooting and optimisation questions for DMD, answered from its protein features.
Which band should guide the blot?
Use 426.8 kDa, the observation attached to the authoritative PB9276 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 426.8 kDa expectation.
Which positive control should I start with?
Start with Heart muscle, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Appendix as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 4-12% gradient consistently across the quick facts, protocol table, and poster.
What transfer method to use for DMD Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9276 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC11606370, PMC4879066, PMC12803508.
Boster reagents
DMD Western Blot Reagents
Human/Mouse/Rat-reactive DMD Western blot reagents with authoritative product imagery.
Real WB data
Anti-Dystrophin/DMD Antibody Picoband®
Cat # PB9276
Reactivity: Human, Mouse, Rat
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P11532
- Human Protein Atlas — DMD
- PB9276 product record
- PMC11606370 — Quantitative proteomics analysis reveals the pathogenesis of obstructed defecation syndrome caused by abnormal expression of dystrophin.
- PMC4879066 — An immunochemical approach to detect oxidized protein tyrosine phosphatases using a selective C-nucleophile tag.
- PMC12803508 — Obestatin Treatment Counteracts Muscle Wasting by Reactivation of Autophagy in Duchenne Muscular Dystrophy.